Syndeio Biosciences is a newly launched biotech company pioneering precision neurotherapeutics.
Syndeio Biosciences has raised $90.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2025.
Syndeio Biosciences's investors include Eli Lilly, AbbVie, Catalio Capital Management, Palo Santo Fund, Innoviva.
Syndeio Biosciences is headquartered in Indianapolis, United States.
Syndeio Biosciences is a newly launched biotech company pioneering precision neurotherapeutics.
Syndeio Biosciences is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Syndeio Biosciences — Funding & Investors." VCBacked, May 27, 2025, https://www.vcbacked.co/company/syndeio-biosciences. Accessed September 13, 2026.
VCBacked. (2025). Syndeio Biosciences — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/syndeio-biosciences
{{cite web |title=Syndeio Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/syndeio-biosciences |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated